Skip to main content

Table 4 Studies evaluating antitumor activity of bisphosphonates in breast cancer

From: Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial

Study/clinical trial

ZO-FAST

ABCSG-12

GAIN

NSABP-B34

AZURE

Saarto [32]

Diel [33]

Kristensen [34]

Powles [35]

N

1065

1803

3023

3323

3360

299

302

953

1069

Bisphosphonate

Zoledronate i.v.

Zoledronate i.v.

Ibandronate p.o.

Clodronate p.o.

Zoledronate i.v.

Clodronate p.o.

Clodronate p.o.

Pamidronate p.o.

Clodronate p.o.

Duration of therapy

5 years

3 years

2 years

3 years

5 years

3 years

2 years

4 years

2 years

Adjuvant therapy

Endocrine (AI)

Endocrine (Tam vs. AI +GnRH-Anal.)

Dose-dense doseintense CTX

CTX +/- Endocrine

CTX +/- Endocrine

CTX +/- Endocrine

CTX +/- Endocrine

CTX

CTX +/- Endocrine

Follow up

60 months

84 months

39 months

91 months

60 months

120 months

103 months

n.d.

66 months

Premenopausal

-

Yes (DFS, OS)

No

No

No

No

Yes (OS)

No

Yes (OS, bonemetastasis free survival)

Postmenopausal

Yes (DFS)

-

No (Trend > 60 yrs.)

Yes (> 50 yrs. DFS, but not OS)

Yes (DFS, OS)

   Â